Patrys's PAT-SM6 found safe in myeloma trial

Patrys (ASX:PAB) has revealed that a phase I/IIa trial of its PAT-SM6 drug candidate in multiple myeloma met its primary endpoints of safety and tolerability.

Results from the open-label escalating dose study in 12 patients have been published in the Haematologica journal.

PAT-SM6 was found to be safe and well tolerated at each dose level administered - 0.3, 1, 3 and 6 mg/kg - and the maximum tolerated dose was not reached.

Four of the 12 patients had stable disease after PAT-SM6 treatment across the dose cohorts of over 1 mg/kg, according to the International Myeloma Working Group criteria.

PAT-SM6 targets the GRP78 protein, which plays a role in resistance in many cancers. This could make it an ideal complementary drug in therapeutic strategies for the difficult-to-treat multiple myeloma.

The published study also includes observations on PAT-SM6’s possible role in overcoming tumour resistance.

As well as its clinical program, Patrys has been building up its patent profile for PAT-SM6 in Australia, Europe, North America and Japan.

Patrys (ASX:PAB) shares were trading 5.88% lower at $0.016 as of around 12.30 pm on Wednesday.